The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer

References

• Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85:1.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941‑53. doi:10.1002/ijc.31937
   Web of Science ®Google Scholar
• Olaussen KA, Mountzios G, Soria J-C. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med. 2007;13(4):284‑9.
   Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353(2):123‑32.
   Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet. 2008;372(9652):1809‑18.
   Web of Science ®Google Scholar
• Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006;22(3):561‑73.
   Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947‑57.
   Web of Science ®Google Scholar
• Paez JG. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497‑500.
   Web of Science ®Google Scholar
• Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(15):2442‑9.
   Google Scholar
• Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet Lond Engl. 2016;387(10026):1415‑26.
   Google Scholar
• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(8):1056‑64.
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627‑39.
   Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823‑33. doi:10.1056/NEJMoa1606774
   Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040‑51.
   Web of Science ®Google Scholar
• Aguiar PN, De Mello RA, Hall P, Tadokoro H, de Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9(6):499‑506.
   Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847‑56.
   Web of Science ®Google Scholar
• Mascaux C, Angelova M, Vasaturo A, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019;571(7766):570‑5.
   Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2012;13(3):239‑46.
   Web of Science ®Google Scholar
• Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213‑22.
   Web of Science ®Google Scholar
• Paz-Ares L, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(2):270‑7.
   Google Scholar
• Urata Y, Katakami N, Morita S, et al. Randomized Phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(27):3248‑57. doi:10.1200/JCO.2015.63.4154
   Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi:10.1126/scitranslmed.3002003
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629‑40. doi:10.1056/NEJMoa1612674
   Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113‑25.
   Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41‑50. doi:10.1056/NEJMoa1913662
   Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167‑77.
   Web of Science ®Google Scholar
• Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet Lond Engl. 2017;389(10072):917‑29.
   Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829‑38. doi:10.1056/NEJMoa1704795
   Web of Science ®Google Scholar
• Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(11):2214‑22.
   Google Scholar
• Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027‑39.
   Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-Line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018‑29.
   Web of Science ®Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118‑33. doi:10.1158/2159-8290.CD-16-0596
   Web of Science ®Google Scholar
• Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter Phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(22):2490‑8.
   Google Scholar
• Descourt R, Perol M, Rousseau-Bussac G, et al. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: a multicentric real-world study (BRIGALK study). Lung Cancer Amst Neth. 2019;136:109‑14.
   Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global Phase 2 study. Lancet Oncol. 2018;19(12):1654‑67.
   Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963‑71. doi:10.1056/NEJMoa1406766
   Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three Phase 1-2 trials. Lancet Oncol. 2020;21(2):261‑70.
   Web of Science ®Google Scholar
• Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984‑93.
   Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307‑16. doi:10.1016/S1470-2045(17)30679-4
   Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl. 2016;387(10027):1540‑50.
   Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl. 2017;389(10066):255‑65.
   Google Scholar
• Kerr KM, Tsao M-S, Nicholson AG, et al. Programmed death-Ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(7):985‑9.
   Google Scholar
• Jeanson A, Tomasini P, Souquet-Bressand M, et al. Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(6):1095‑101.
   Google Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351‑7.
   Web of Science ®Google Scholar
• Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(12):1985‑91.
   Google Scholar
• Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47‑51.
   Web of Science ®Google Scholar
• Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944‑57. doi:10.1056/NEJMoa2002787
   Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations. N Engl J Med. 2020;383(10):931‑43. doi:10.1056/NEJMoa2004407
   Web of Science ®Google Scholar
• Lu S, Fang J, Li X, et al. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). J Clin Oncol. 2020;38(15_suppl):9519‑9519. doi:10.1200/JCO.2020.38.15_suppl.9519
   Web of Science ®Google Scholar
• Mazieres J, Cropet C, Montané L, et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(2):289‑94.
   Google Scholar
• Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2017;5(1):42‑50.
   Web of Science ®Google Scholar
• Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17(12):1653‑60.
   Web of Science ®Google Scholar
• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383(9):813‑24.
   Web of Science ®Google Scholar
• Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836‑49.
   Web of Science ®Google Scholar
• Haratake N, Seto T. NTRK fusion-positive non–small-cell lung cancer: the diagnosis and targeted therapy. Clin Lung Cancer. 2021;22(1):1‑5.
   Web of Science ®Google Scholar
• Jebbink M, de Langen AJ, Boelens MC, Monkhorst K, Smit EF. The force of HER2 - A druggable target in NSCLC? Cancer Treat Rev. 2020;86:101996.
   PubMed Web of Science ®Google Scholar
• Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638‑46.
   Web of Science ®Google Scholar
• Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, Phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688‑701.
   Web of Science ®Google Scholar
• Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol. 2020;38(15_suppl):9504‑9504. doi:10.1200/JCO.2020.38.15_suppl.9504
   Google Scholar
• Riely GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (TAK-788) in previously treated non–small cell lung cancer with EGFR Exon 20 insertion mutations from a Phase I/II trial. Cancer Discov. 2021;11(7):1688–1699. doi:10.1158/2159-8290.CD-20-1598
   PubMed Web of Science ®Google Scholar
• Yun J, Lee S-H, Kim S-Y, et al. Antitumor activity of Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10(8):1194‑209.
   Web of Science ®Google Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207‑17. doi:10.1056/NEJMoa1917239
   Web of Science ®Google Scholar
• Wang Y, Yang N, Zhang Y, et al. Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020;15(8):1369‑75.
   Google Scholar
• Wu Y-L, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8(11):1132‑43.
   Web of Science ®Google Scholar
• Sequist LV, Han J-Y, Ahn M-J, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373‑86.
   Web of Science ®Google Scholar
• Drilon A, Ou S-HI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov. 2018;8(10):1227‑36.
   Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500‑1. doi:10.1056/NEJMc1713444
   Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020‑31. doi:10.1056/NEJMoa1910231
   PubMed Web of Science ®Google Scholar
• Zeng D-Q, Yu Y-F, Ou Q-Y, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget. 2016;7(12):13765‑81.
   Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930‑40. doi:10.1172/JCI91190
   Web of Science ®Google Scholar
• Gu X, Sun S, Gao X-S, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3430 patients. Sci Rep. 2016;6:23893.
   Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(Supplement_4):iv192‑237.
   Google Scholar
• Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn JMD. 2015;17(3):251‑64.
   Web of Science ®Google Scholar
• Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med. 2019;27(148):167‑70.
   Web of Science ®Google Scholar
• Massard C, Michiels S, Ferté C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586‑95.
   Web of Science ®Google Scholar
• Middleton G, Fletcher P, Popat S, et al. The national lung matrix trial of personalized therapy in lung cancer. Nature. 2020;583(7818):807‑12.
   Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(11):1491‑505.
   Google Scholar
• Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017.
   Web of Science ®Google Scholar
• van der Velden DL, van Herpen CML, van Laarhoven HWM, et al. Molecular Tumor Boards: current practice and future needs. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(12):3070‑5.
   Google Scholar
• Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385‑9.
   Web of Science ®Google Scholar
• Sorber L, Zwaenepoel K, Deschoolmeester V, et al. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer Amst Neth. 2017;107:100‑7.
   Web of Science ®Google Scholar
• Goldberg SB, Narayan A, Kole AJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(8):1872‑80.
   Google Scholar
• Sicard G, Fina F, Fanciullino R, Barlesi F, Ciccolini J. Like a rolling stone: sting-cgas pathway and cell-free DNA as biomarkers for combinatorial immunotherapy. Pharmaceutics. 2020;12:8.
   Web of Science ®Google Scholar